The government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.
Covaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.
In April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.
A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.
The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer-reviewed.
The DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.
At present, the gap between the second Covid jab and the precaution dose is nine months.
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.
Recently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
Earlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.
The company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
Covaxin has already been granted Emergency Use Listing (EUL) in 13 countries.
An intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
The DCGI approval came after the Subject Expert Committee (SEC) on COVID-19 recommended granting regular market approval to Covishield and Covaxin.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
The BJP emerged as the single largest party bagging 384 seats against the MVA tally of 944 comprising Nationalist Congress Party's 344, Congress' 316 and Shiv Sena's 284 seats.
Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.
Earlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.
Top News
Latest News
